

The Royal Marsden NHS Foundation Trust
Drug & Therapeutic Committee minutes
28th May 2020

Present: Consultant Breast and AOS (chair)
Consultant Haemato-oncology
Drug Resource Manager (secretary)
Consultant Palliative Medicine
Consultant Pharmacist
Consultant Paediatrics & Palliative care
Governance & Medicines Safety Pharmacist
Consultant Medical oncology
Consultant Microbiologist
Advanced Nurse Practitioner – Haemato-oncology

In attendance:

1. Minutes of the April meeting

Minutes – approved.

2. Conflict of Interest.

No conflicts raised.

3. NICE Guidance update.

1. TA628: Lorlatinib for previously treated ALK+ve advanced NSCL
2. TA629: Obinatumab with bendamustine for treating follicular lymphoma
3. TA630: Larotrectinib for treating NTRK fusion +ve solid tumours (refer to guidance in relation to phased introduction)

Relevant clinical leads made aware of the guidance.

4. One off drug use requests.

1. Tolvaptan in severe SIADH refractory to fluid restriction and demeclocycline.
Requested that a full proposal to be developed to come to a future meeting.
2. Eculizumab (via CUP) in transplant related thrombotic microangiopathy.
3. Ivosidenib (via CUP) in IDH1 mutated AML.
4. Belantini (via CUP) in relapsed refractory myeloma.

All requests approved.

5. Osimertinib (via compassionate supply). Presented by the Lung unit.

Proposed for use as 1st line treatment of locally advanced or metastatic EGFR +ve NSCLC, in line with the compassionate supply program.

Action:

Approved.

6. Niraparib (via compassionate supply). Presented by the Gynaecology unit.

Proposed for use as maintenance in high grade serous ovarian ca, fallopian tube ca, or primary peritoneal ca. in patients who have had complete or partial response to front line platinum containing therapy with a nonBRCA mutation, in line with the compassionate supply program.

Action:

Approved.

7. Bortezomib. Presented by the Haemato-oncology unit.

Proposed for use to treat post-transplant immune complications including Auto Immune Haemolytic Anaemia, Immune Thrombocytopenic Purpura and Graft Versus Host Disease when refractory to the standard lines of treatment including corticosteroids, rituximab and immunosuppressive agents.

Action:

Approved.

8. Lipegfilgrastim. Presented by the Haemato-oncology unit.

Proposed for use at the trust in line with the licensed indication i.e. reduction in the duration of neutropenia and incidence of Febrile Neutropenia in patients treated with chemotherapy for malignancy (with the exception of CML & MDS).

Action:

Approved.

9. Acalabrutinib (via compassionate supply). Presented by the Haemato-oncology unit.

Proposed for use as monotherapy as 1st line treatment of CLL with no TP53 mutation deletion, in line with the compassionate supply program.

Action:

Approved.

10. Mouthcare guidelines. Presented by Nursing & Pharmacy.

Guidance developed as an update to previous trust guidance, the new guidance has the addition of Episil as an additional agent. The aim is for all patients to use the same treatments as a prevention strategy, with good oral hygiene being the key in prevention, and patient comfort and compliance and reduced patient admissions for mucositis being the goal.

Action:

Approved.

11. Management of Anaemia in Oncology and Onco Surgery Patients. Presented by Nursing.

Guidance developed in order to bring the surgical and oncology guidelines for the management of anaemia into one policy. This has been reviewed by clinical, nursing and pharmacy leads prior to publication. The guidance also incorporates the latest 2020/21 CQUIN guidance.

Action:

Approved.

12. AOB

Date of the Next Meeting:

Tuesday 23rd of June (pm), 15:00 – 17:00

Minutes Approved	DTC chair: Tuesday 23 rd June 2020
------------------	---

Date of next meeting 23 rd June 2020.
--